Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
Delayed Quote. Delayed Nasdaq - 08/14 04:00:00 pm
425.16 USD   -2.32%
08/12DEXCOM :  Dexcom Appoints Karen Dahut to Board of Directors
BU
08/10DEXCOM : Announces Upcoming Conference Presentation
BU
07/28DEXCOM : 2Q Earnings Snapshot
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2020 08/11/2020 08/12/2020 08/13/2020 08/14/2020 Date
421.22(c) 411.15(c) 427.89(c) 435.28(c) 425.16(c) Last
1 113 658 818 513 616 376 605 823 472 670 Volume
-4.42% -2.39% +4.07% +1.73% -2.32% Change
More quotes
Financials (USD)
Sales 2020 1 870 M - -
Net income 2020 174 M - -
Net Debt 2020 132 M - -
P/E ratio 2020 246x
Yield 2020 -
Sales 2021 2 303 M - -
Net income 2021 284 M - -
Net cash position 2021 354 M - -
P/E ratio 2021 151x
Yield 2021 -
Capitalization 41 675 M 41 675 M -
EV / Sales 2020 22,4x
EV / Sales 2021 17,9x
Nbr of Employees 3 900
Free-Float 98,7%
More Financials
Company
DexCom, Inc. specialises in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 78.7% of net sales.  
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Toute l'actualité sur DEXCOM, INC.
08/12DEXCOM :  Dexcom Appoints Karen Dahut to Board of Directors
BU
08/10DEXCOM : Announces Upcoming Conference Presentation
BU
07/28DEXCOM : 2Q Earnings Snapshot
AQ
07/28DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
07/28DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
07/28DEXCOM : Reports Second Quarter 2020 Financial Results
BU
07/27DEXCOM : Lawyers Investigate Potential Device Defects After Recall Of Dexcom Glu..
AQ
07/23DEXCOM, INC. : half-yearly earnings release
07/16DEXCOM : Health Canada Authorizes Interim Use of Dexcom G6 CGM by Pregnant Women..
AQ
06/30DEXCOM SCHEDULES SECOND QUARTER 2020 : 30 p.m. Eastern Time
BU
06/30DEXCOM INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/04DEXCOM : Announces Upcoming Conference Presentation
BU
05/22DEXCOM INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/15DEXCOM INC : Entry into a Material Definitive Agreement, Creation of a Direct Fi..
AQ
05/12DEXCOM : Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior No..
BU
More news
News in other languages on DEXCOM, INC.
08/12DEXCOM :  Dexcom Appoints Karen Dahut to Board of Directors
08/10DEXCOM : Announces Upcoming Conference Presentation
07/28DEXCOM : 2Q Earnings Snapshot
07/28DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
07/28DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
More news
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 460,95 $
Last Close Price 435,28 $
Spread / Highest target 24,1%
Spread / Average Target 5,90%
Spread / Lowest Target -52,4%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer & Executive VP
Shelly R. Selvaraj Senior Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.98.99%40 967
ABBOTT LABORATORIES16.39%179 001
MEDTRONIC PLC-10.72%135 860
BECTON, DICKINSON AND COMPANY-3.54%76 041
BAXTER INTERNATIONAL INC.1.22%42 847
HOYA CORPORATION2.87%37 391